



January 17, 2024

**Re : Updated safety information regarding PROSCAR® (finasteride) - DIN 02010909**

As of November 24, 2023, the Product Monograph of Organon's product, PROSCAR® (finasteride) has been updated to reflect safety concerns related to finasteride-containing products and suicide, suicidal ideation, and self-injury related events further to Health Canada's published Summary Safety Review for finasteride.

PROSCAR® is indicated:

- As monotherapy for the treatment and control of benign prostatic hyperplasia (BPH) and for the prevention of urologic events to:
  - Reduce the risk of acute urinary retention;
  - Reduce the risk of surgery including transurethral resection of the prostate (TURP) and prostatectomy.
- PROSCAR® causes regression of the enlarged prostate, improves urinary flow and improves the symptoms associated with BPH.
- PROSCAR® administered in combination with the alpha-blocker doxazosin is indicated to reduce the risk of symptomatic progression of BPH (a confirmed  $\geq 4$  point increase in American Urological Association (AUA) symptom score).

For the complete prescribing information and information available for the patients/caregivers please consult the [PROSCAR® Product Monograph](#). The Product Monograph can be found on the [Organon Website](#), or by contacting Organon Canada at 1-844-820-5468.

Healthcare Professionals who have medical enquiries regarding PROSCAR® can contact our Medical Information Department at 1-844-820-5468, or via email at [medinfocanada@organon.com](mailto:medinfocanada@organon.com).

For questions or concerns, patients are encouraged to contact their healthcare professional.

® N.V. Organon. Used under license.

© 2024 Organon group of companies. All rights reserved.